Danish Centre for Particle Therapy, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Acta Oncol. 2023 Nov;62(11):1511-1519. doi: 10.1080/0284186X.2023.2238884. Epub 2023 Aug 9.
The aim of this retrospective registry-based Danish patterns of care study was (1) to evaluate the real-world utilisation of short-course hypofractionated radiotherapy (HFRT) in glioblastoma (GBM) patients over time, and (2) to evaluate the impact of short-course HFRT by assessing trends in multimodality treatment utilisation, compliance, and outcome.
Data of all adults with newly diagnosed pathology-confirmed GBM between 2011 and 2019 were extracted from the nationwide Danish Neuro-Oncology Registry. Short-course HFRT was defined as a fraction size of > 2 Gy to a planned dose of > 30 Gy. Patterns of care were assessed. To analyse trends in the assignment to short-course HFRT, and in radiotherapy (RT) compliance, multivariable logistic regression was applied. To analyse trends in survival, multivariable Cox regression was used.
In this cohort of 2416 GBM patients, the utilisation of short-course HFRT significantly increased from ca. 10% in 2011 to 33% in recent years. This coincided with the discontinued use of palliative regimens and a decreased use of conventional fractionation. The proportion of patients proceeding to RT remained stable at ca. 85%. The proportion of patients assigned to radiotherapy (CRT) remained stable at ca. 60%; the use of CRT increased with ca. 10%, while the use of CRT decreased with ca. 10%. Compliance with conventionally fractionated and short-course HFRT was respective 92% and 93%, and significantly increasing in recent years. In the complete cohort, the median overall survival remained stable at ca. 11 months. Assignment to was independently associated with shorter survival.
In Denmark, the use of short-course HFRT significantly increased in recent years. Nonetheless, the overall utilisation of RT and chemotherapy did not increase on a population level. Nor did survival change. In contrast, compliance with both conventionally fractionated RT and short-course HFRT increased.
本项基于丹麦回顾性登记的实际情况研究旨在(1)评估胶质瘤(GBM)患者短程低分割放疗(HFRT)的实际应用随时间的变化,(2)通过评估多模式治疗应用、依从性和结局的趋势,评估短程 HFRT 的影响。
从全国性丹麦神经肿瘤学登记处提取了 2011 年至 2019 年间所有新诊断为病理证实的 GBM 成人患者的数据。短程 HFRT 的定义为分次剂量>2Gy 至计划剂量>30Gy。评估了治疗模式。为了分析短程 HFRT 分配和放疗(RT)依从性的趋势,采用多变量逻辑回归。为了分析生存趋势,采用多变量 Cox 回归。
在该队列的 2416 名 GBM 患者中,短程 HFRT 的使用率从 2011 年的约 10%显著增加到近年的 33%。这与姑息治疗方案的停用以及常规分割放疗的使用率降低同时发生。进行 RT 的患者比例保持在约 85%的稳定水平。分配至放疗(CRT)的患者比例保持在约 60%的稳定水平; CRT 的使用率增加了约 10%,而 CRT 的使用率降低了约 10%。常规分割和短程 HFRT 的依从性分别为 92%和 93%,且近年来显著增加。在全队列中,中位总生存期保持在约 11 个月的稳定水平。接受 CRT 治疗与较短的生存时间独立相关。
在丹麦,近年来短程 HFRT 的使用显著增加。然而,在人群水平上,RT 和化疗的总体使用率并没有增加。生存也没有改变。相反,常规分割 RT 和短程 HFRT 的依从性均有所提高。